“Despite trading at a premium to its peers, Thomson Medical is expected to deliver ebitda growth with a compound annual growth rate (CAGR) of 11% between FY2024 to FY2026, much stronger than some of its peers with maturing operations,” the analysts write in their Feb 14 report.
DBS Group Research analysts Rachel Tan and Amanda Tan note the strong growth potential of Thomson Medical Group (SGX:A50
) following the company’s completed acquisition of the FV Hospital in Vietnam on Jan 17, the biggest healthcare acquisition to-date in Vietnam and Southeast Asia since 2010.
The analysts have a fair value estimate of 8 cents, based on 23 times FY2025 earnings before interest, taxes, depreciation and amortisation (ebitda), which is around 0.5 standard deviation (s.d.) below the historical mean.
